Lipocine
LPCN
49 hedge funds and large institutions have $4.16M invested in Lipocine in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 4 closing their positions.
5,133% more call options, than puts
Call options by funds: $471K | Put options by funds: $9K
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
7% more funds holding
Funds holding: 46 → 49 (+3)
0.02% less ownership
Funds ownership: 0.72% → 0.7% (-0.02%)
14% less capital invested
Capital invested by funds: $4.85M → $4.16M (-$694K)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| 1 |
B
Bailard
Foster City,
California
|
+$35.6K |
| 2 |
WP
Wealthspan Partners
Davenport,
Iowa
|
+$31.7K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$7.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.14K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$80.9K |
| 2 |
VF
Virtu Financial
New York
|
-$42K |
| 3 |
Two Sigma Advisers
New York
|
-$20.2K |
| 4 |
WE
Wealth Effects
Boston,
Massachusetts
|
-$15.9K |
| 5 |
Two Sigma Investments
New York
|
-$15.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Walleye Trading
New York
| – | -$44 | -6 | Closed |
|
LPCN Hedge Fund Activity: Q4 2022 in Review
49 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2022, worth a combined $4.16M — down 14% from $4.85M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LPCN positions and 4 closed out — a net gain of 3 holders — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Bailard, opening a new position worth an estimated $35.6K. The largest seller was Citadel Advisors, cutting an estimated $80.9K.
- 49 institutional investors held Lipocine (LPCN) as of Q4 2022, up from 46 in Q3 2022.
- Funds reported $4.16M of Lipocine stock for Q4 2022, down 14% quarter-over-quarter.
- 7 funds opened new Lipocine positions in Q4 2022 and 4 closed out, a net change of +3 holders.
- The largest Lipocine buyer in Q4 2022 was Bailard, an estimated $35.6K added.
- The largest Lipocine seller in Q4 2022 was Citadel Advisors, an estimated $80.9K sold.
Based on aggregated 13F filings for Q4 2022.